Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2018 3
2019 2
2020 2
2021 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles.
Rijcken CJF, De Lorenzi F, Biancacci I, Hanssen RGJM, Thewissen M, Hu Q, Atrafi F, Liskamp RMJ, Mathijssen RHJ, Miedema IHC, Menke-van der Houven van Oordt CW, van Dongen GAMS, Vugts DJ, Timmers M, Hennink WE, Lammers T. Rijcken CJF, et al. Among authors: atrafi f. Adv Drug Deliv Rev. 2022 Dec;191:114613. doi: 10.1016/j.addr.2022.114613. Epub 2022 Nov 4. Adv Drug Deliv Rev. 2022. PMID: 36343757 Review.
Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
Atrafi F, Boix O, Subbiah V, Diamond JR, Chawla SP, Tolcher AW, LoRusso PM, Eder JP, Gutierrez M, Sankhala K, Rajagopalan P, Genvresse I, Langer S, Mathijssen RHJ, Verweij J, Bruns I, Lolkema MP. Atrafi F, et al. Clin Cancer Res. 2022 Jul 1;28(13):2969. doi: 10.1158/1078-0432.CCR-22-1792. Clin Cancer Res. 2022. PMID: 35775194 No abstract available.
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
Atrafi F, Boix O, Subbiah V, Diamond JR, Chawla SP, Tolcher AW, LoRusso PM, Eder JP, Gutierrez M, Sankhala K, Rajagopalan P, Genvresse I, Langer S, Mathijssen RHJ, Verweij J, Bruns I, Lolkema MP. Atrafi F, et al. Clin Cancer Res. 2021 Dec 1;27(23):6366-6375. doi: 10.1158/1078-0432.CCR-20-4185. Epub 2021 Sep 13. Clin Cancer Res. 2021. PMID: 34518310 Clinical Trial.
Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors.
Atrafi F, van Eerden RAG, van Hylckama Vlieg MAM, Oomen-de Hoop E, de Bruijn P, Lolkema MP, Moelker A, Rijcken CJ, Hanssen R, Sparreboom A, Eskens FALM, Mathijssen RHJ, Koolen SLW. Atrafi F, et al. Clin Cancer Res. 2020 Jul 15;26(14):3537-3545. doi: 10.1158/1078-0432.CCR-20-0008. Epub 2020 Apr 22. Clin Cancer Res. 2020. PMID: 32321718 Clinical Trial.
A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors.
Atrafi F, Groen HJM, Byers LA, Garralda E, Lolkema MP, Sangha RS, Viteri S, Chae YK, Camidge DR, Gabrail NY, Hu B, Tian T, Nuthalapati S, Hoening E, He L, Komarnitsky P, Calles A. Atrafi F, et al. Clin Cancer Res. 2019 Jan 15;25(2):496-505. doi: 10.1158/1078-0432.CCR-18-2014. Epub 2018 Oct 16. Clin Cancer Res. 2019. PMID: 30327308 Clinical Trial.
A single digital droplet PCR assay to detect multiple KIT exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors.
Boonstra PA, Ter Elst A, Tibbesma M, Bosman LJ, Mathijssen R, Atrafi F, van Coevorden F, Steeghs N, Farag S, Gelderblom H, van der Graaf WTA, Desar IME, Maier J, Overbosch J, Suurmeijer AJH, Gietema J, Schuuring E, Reyners AKL. Boonstra PA, et al. Among authors: atrafi f. Oncotarget. 2018 Feb 14;9(17):13870-13883. doi: 10.18632/oncotarget.24493. eCollection 2018 Mar 2. Oncotarget. 2018. PMID: 29568401 Free PMC article.
11 results